Femasys Doubles Enrollment Sites in FemBloc Pivotal Trial

  • Femasys Inc. has doubled the number of actively enrolling sites in its FemBloc FINALE Pivotal Trial to twelve across the United States.
  • New sites include Baylor Research Institute and Columbia University Medical Center, joining existing academic and private clinical practices.
  • The trial is evaluating the safety and effectiveness of FemBloc, a non-surgical permanent birth control solution.
  • FemBloc received regulatory approvals in Europe, the UK, and New Zealand in 2025.

Femasys' expansion of enrollment sites in the FemBloc FINALE Pivotal Trial marks a significant step in its U.S. regulatory strategy. The inclusion of prominent academic centers underscores growing clinical interest in non-surgical permanent birth control solutions. This move is part of a broader trend towards innovative, less invasive reproductive health options, which could reshape the market dynamics for permanent birth control.

Regulatory Strategy
Whether Femasys can leverage European approvals and U.S. trial data to accelerate FDA approval for FemBloc.
Clinical Trial Execution
The pace at which Femasys can enroll and complete the FINALE trial, given the expanded site network.
Market Adoption
How post-market real-world data from Europe will support broader adoption of FemBloc globally.